Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Galactose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL1883668 | 1.00 | PDE4A (0.38) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Demannose SCHEMBL2878983 | 0.94 | LMNA (0.39) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Demannose SCHEMBL27278309 | 0.94 | LMNA (0.39) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Demannose SCHEMBL1422978 | 0.93 | PDE4A (0.35) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Galactose SCHEMBL31555927 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Galactose SCHEMBL423422 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Galactose SCHEMBL30458008 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Demannose SCHEMBL13277644 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Demannose SCHEMBL3630269 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Demannose SCHEMBL21456966 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551228-B1 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | UNIV NEW YORK (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8252909-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-7771726-B2 | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases | NEW YORK UNIVERSITY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7273852-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050192248-A1 | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases | NYU MEDICAL CENTER (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1551228-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | New York University (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2004-07-01 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| WO-2003105769-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | PDE4A 1969/4885LMNA 4566/4885USP2 1098/4885 |
| US-20050192248-A1 | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases | CD4, CD81, CD69 | PDE4A 4177/4885LMNA 4415/4885USP2 3133/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | PDE4A 1969/4885LMNA 4566/4885USP2 1098/4885 |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | UGT8, UGCG, SGMS1 | PDE4A 4642/4885LMNA 4375/4885USP2 3332/4885 |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | CCR8, UGT8, H1-10 | PDE4A 4653/4885LMNA 4286/4885USP2 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.